Q3/2024 9/30/2024 EPS -0.960 ZacksConsensus -0.710 ActVsEst (0.250) - Miss
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.MarketBeat
- Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Dyne Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
DYN
Earnings
- 8/12/24 - Beat
DYN
Sec Filings
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- 11/18/24 - Form 144
- DYN's page on the SEC website